Sphere Fluidics Launches Cyto-CellectPLUS to Accelerate Cell Line Development Workflows
Expanding on Sphere Fluidics’ original Cyto-Cellect Human IgGκ Detection Kit, Cyto-CellectPLUS now detects both the IgG κ and λ light chains to support a broader range of projects.
- Expanding on Sphere Fluidics’ original Cyto-Cellect Human IgGκ Detection Kit, Cyto-CellectPLUS now detects both the IgG κ and λ light chains to support a broader range of projects.
- The assay is fully compatible with existing Cyto-Mine functionality, including single cell dispensing into 96-well and 384-well plates, allowing it to seamlessly integrate into customers’ existing cell line development workflows and conforms to relevant regulatory requirements by being animal-origin-free.
- This accelerated throughput is already widely recognized across a variety of research areas, including antibody discovery, cell line development, cell engineering and synthetic biology.
- This launch demonstrates ongoing innovation and expansion of our capabilities, in line with our plans to accelerate commercial roll out.